文献速递耳科与耳神经小儿耳鼻咽喉

ValEAR试验中先天性巨细胞病毒检测的结果

Congenital Cytomegalovirus Testing Outcomes From the ValEAR Trial.
PubMed 文献 · Otolaryngol Head Neck Surg · 2024-02-28

该研究前瞻性调查了参与美国国立卫生研究院ValEAR临床试验的82家分娩医院,比较普遍筛查、听力靶向检测(HT-cCMV)和延迟干血斑(DBS)检测三种方式的cCMV阳性率。结果显示三种方式阳性率分别为0.5%、1.5%和7.3%,且特定医嘱套餐和严格的检测后流程与HT-cCMV筛查项目的成功相关。

要点

  • 普遍筛查、听力靶向检测和延迟干血斑检测的cCMV阳性率分别为0.5%、1.5%和7.3%。
  • 疫情期间普遍筛查的cCMV阳性率低于疫情前,但各检测方式的阳性率均无统计学显著下降。
  • 对于HT-cCMV检测,独特的医嘱套餐和严格的检测后流程与成功的筛查项目相关。

核心结论

  • 三种检测方式的cCMV阳性率存在差异,与文献中报道的队列研究相当。
  • 疫情期间普遍CMV患病率下降但无统计学显著性。
  • 具有特定CMV检测医嘱套餐(由初级保健医生开具检测、护士协助检测流程)的机构表现出更高的HT-cCMV检测率。

研究设计与样本

  • 研究设计为前瞻性调查,对参与美国国立卫生研究院ValEAR临床试验的分娩医院进行调研。
  • 共调查82家分娩医院,调查时间为2019年2月至2021年12月。

主要发现

  • 普遍筛查的cCMV阳性率为0.5%,HT-cCMV检测为1.5%,延迟DBS检测为7.3%。
  • 普遍CMV筛查的阳性率在COVID-19疫情期间低于疫情前报告的水平。
  • 疫情期间任何检测方式的阳性率均无统计学显著下降。
  • 对于HT-cCMV检测,独特的医嘱套餐和严格的检测后流程与成功的筛查项目相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the positivity rate of congenital cytomegalovirus (cCMV) testing among universal, hearing-targeted CMV testing (HT-cCMV) and delayed targeted dried blood spot (DBS) testing newborn screening programs, and to examine the characteristics of successful HT-cCMV testing programs. STUDY DESIGN: Prospective survey of birth hospitals performing early CMV testing. SETTING: Multiple institutions. METHODS: Birth hospitals participating in the National Institutes of Health ValEAR clinical trial were surveyed to determine the rates of cCMV positivity associated with 3 different testing approaches: universal testing, HT-cCMV, and DBS testing. A mixed methods model was created to determine associations between successful HT-cCMV screening and specific screening protocols. RESULTS: Eighty-two birth hospitals were surveyed from February 2019 to December 2021. Seven thousand six hundred seventy infants underwent universal screening, 9017 infants HT-cCMV and 535 infants delayed DBS testing. The rates of cCMV positivity were 0.5%, 1.5%, and 7.3%, respectively. The positivity rate for universal CMV screening was less during the COVID-19 pandemic than that reported prior to the pandemic. There were no statistically significant drops in positivity for any approach during the pandemic. For HT-cCMV testing, unique order sets and rigorous posttesting protocols were associated with successful screening programs. CONCLUSION: Rates of cCMV positivity differed among the 3 approaches. The rates are comparable to cohort studies reported in the literature. Universal CMV prevalence decreased during the pandemic but not significantly. Institutions with specific order set for CMV testing where the primary care physician orders the test and the nurse facilitates the testing process exhibited higher rates of HT-cCMV testing.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Orb QT, Pesch M, Allen CM, et al. Congenital Cytomegalovirus Testing Outcomes From the ValEAR Trial. Otolaryngol Head Neck Surg. 2024. PMID: 38415855. doi:10.1002/ohn.670

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。